Enhanced human immunodeficiency virus (HIV)-specific immunity may be required for HIV eradication. Administration of autologous, ex vivo expanded, virus-specific, cytotoxic T-lymphocytes derived from HIV-infected patients on suppressive antiretroviral therapy (HXTCs) are a powerful tool for proof-of-concept studies. Broadly specific, polyclonal HXTCs resulting from ex vivo expansion demonstrated improved control of autologous reservoir virus compared to bulk CD8 + T cells in viral inhibition assays. Furthermore, patient-derived HXTCs were able to clear latently infected autologous resting CD4 + T cells following exposure to the latency-reversing agent, vorinostat. HXTCs will be ideal reagents to administer with precise control in future in vivo studies in combination with latency-reversing agents.
The latent human immunodeficiency virus (HIV) reservoir remains a major obstacle to eradication of persistent infection [1] . Therapies that clear latent HIV infection may require both a means to reactivate virus protein expression, and an immune response that recognizes and kills infected cells as they leave the latent state [2] . The extant antiviral immune response may be inadequate to clear such latently infected cells [3] .
Augmented, polyclonal, functional antiviral responses have been created by ex vivo expansion of virus-specific T cells. These cells have successfully treated viral infections after hematopoietic stem cell transplantation and Epstein-Barr virus-associated malignancies [4, 5] . The use of ex vivo expanded T cells from HIV-infected individuals in place of potent antiretroviral therapy (ART) was first tested over a decade ago (reviewed in [6] ). These studies established the safety of adoptive transfer of HIVspecific T cells, but cellular therapy by itself had only transient antiviral efficacy, due in part to the reliance on monoclonal T cells, extensive in vitro expansion, and their use in actively viremic patients. In a more recent study, HIV-specific CD8 + T cells derived from ART-suppressed patients were found to be persistent in the blood and capable of homing to rectal tissue following reinfusion, but virologic outcomes were not assessed [7] .
In this study, we examine the ability of functional, broadly specific cytotoxic T cells (HXTCs) derived from 6 HIV+ individuals, clinically diverse but aviremic on durable ART, to target the latent reservoir ex vivo. We find that ex vivo expanded, polyclonal T cells broadly specific for multiple HIV epitopes [8] in Gag, Pol, and Nef (HXTCs) can be produced in clinically relevant numbers. These studies set the stage for testing of HXTCs in ART-suppressed patients. This combination approach may allow clearance of residual low-level viremia and if coadministered with latency reversing agents, might clear the latent reservoir itself
MATERIALS AND METHODS

Patient Population
HXTCs were derived from HIV-infected donors with undetectable plasma viremia (<50 copies/mL) on stable ART. Participants were drawn from cohorts who began treatment within 45 days of diagnosis of acute HIV (AHI) or during chronic HIV infection (CHI). For in vivo vorinostat (VOR) exposure, patients received 3 doses of 400 mg VOR, with a leukapheresis performed at baseline and 6 hours following the third dose. Written informed consent was obtained from each patient and the study approved by the University of North Carolina, Baylor College of Medicine, and Children's National Medical Center Biomedical Institutional Review boards.
Generation of HXTCs
HXTCs were generated as previously described (Supplemental Methods and [8] ). 
Viral Inhibition Assay
Latency Clearance Assay
To measure the reduction in viral recovery in a viral outgrowth assay following the addition of autologous effector cells, resting CD4 + T cells were isolated from a leukapheresis product as previously described [9] and exposed to PHA (4 µg/mL) and IL-2 (60 U/mL) for 24 hours or VOR (335 nM, 6 hours) (Merck Research Laboratories), and plated in a limiting dilution manner at 0.5 to 2.5 × 10 6 cells/well in replicate wells. Drug was then washed off and effectors added (E:T 1:10). Cells were cocultured for 24 hours, then cultured with allogeneic CD8-depleted PBMCs from an HIV-negative donor to amplify virus. Antigen p24 was measured on day 15 for each well.
Proliferation Assay
CD8
+ T cells were stained with 5 µM carboxyfluorescein diacetate succinimidyl diester (CFSE; BioLegend, San Diego, California) and stimulated with 2 µg/mL PHA/50 U/mL IL-2 and assessed at day 3 by an Attune flow cytometer (AB). Data were analyzed with FloJo software.
Statistical Analysis
Statistical comparisons between groups were analyzed using the Wilcoxon signed rank test for latency clearance assays (LCAs) when results were taken in aggregate across patients (n = 6). Significance for each individual patient was analyzed using a 2-tailed Student t test for viral inhibition assays (n = 3 replicates) and based on the variance of the outgrowth assay for LCAs. P < .05 was considered significant.
RESULTS AND DISCUSSION
HXTCs were derived from HIV-infected individuals on ART (Supplementary Table 1 Figure 1A) . HXTC generation was optimized to allow for production of T cells that are capable of further expansion upon restimulation, and HXTCs proliferate normally in response to PHA stimulation (Supplementary Figure 1B) . Clinically relevant numbers of Nef-, Gag-, and Pol-specific HXTCs are recovered after expansion by this method [8] . In these studies, expansions ranging from 40-fold (patient 250) to >200-fold expansion (patients 423 and 492) were obtained. Using a modification of an in vitro viral inhibition assay that has been associated with viral control in vivo [10] , we tested the antiviral capacity of HXTCs against productively infected cells. As viral genomes with mutations that might lead to cytotoxic T-lymphocyte (CTL) escape can be found in the latent reservoir [11] , we examined whether polyclonal HXTCs could recognize and inhibit epitopes derived from the latent reservoir by using AR, harvested from outgrowth assays of autologous resting CD4 + T cells.
In this assay, coculture with HXTCs at an effector to target ratio of 1:1 resulted in a significantly greater reduction of AR production than did unexpanded CD8 + T cells in patient 532 patients resulted in a median 50% reduction in recovery of virus (P < .05; Figure 1B ) in a reproducible manner ( Figure 1D ). Interestingly, HXTCs from 4 of the 6 patients respond to all 3 Figure 2 . Impact of VOR on antiviral capacity of CD8 + T cells. A, CD8 + T cells from a representative patient (532) were pretreated with escalating doses of VOR for 24 hours prior to coculture with autologous CD8-depleted PBMCs superinfected with JR-CSF at an E:T of 1:10 or 1:1. B, The impact of increasing doses of VOR on proliferation of CFSE-labeled CD8 + T cells following stimulation with PHA/IL-2 is shown (C). Antiviral capacity of ex vivo CD8s isolated either before ("Pre-VOR") or 6 hours following a third in vivo dose of VOR given 72 hours apart ("Post-VOR") was compared in a viral inhibition assay. D, "Pre-" and "Post"-VOR CD8s were compared in a latent virus inhibition assays. Error bars represent SEM of n = 3 replicates, p calculated by Student t test. *Denotes P < .01 for CD8s compared to control with no CD8s (except for (A) exposure to 500 nM VOR, P = .03; (C) pre-VOR CD8 at E:T 1:10, P < .05). Abbreviations: CFSE, carboxyfluorescein diacetate succinimidyl diester; IL-2, interleukin 2; PBMCs, peripheral blood mononuclear cells; PHA, phytohemagglutinin; SEM, standard error of the mean; VOR, vorinostat.
cognate antigens, gag, nef, and pol, in in vitro Elispot assays, while HXTCs from patient 423 responded to only nef and those from patient 250 to gag only [8] , perhaps explaining the weaker antiviral activity of HXTCs from patients 250 and 423.
HXTCs led to a reduction in viral recovery in all 6 patients beyond that achievable with unexpanded CD8 + T cells. Unexpanded CD8 + cells exhibited little ability to blunt viral recovery following reactivation of CD4 + T cells by PHA (median 90%, P = NS), consistent with findings in primary cell models of latency [3, 12] and recent studies in which unexpanded T cells from aviremic patients showed no measurable HIV-specific response to cognate peptides in Elispot assays [8] . Strongly enhanced activity was even seen in a CHI patient with a history of a low nadir CD4 count and the HLA-B35*03 allele ( patient 532) associated with rapid disease progression. Due to the need to use allogeneic HIV-seronegative cells to efficiently recover latent HIV, we cannot exclude a contribution of immune response to allogeneic stimuli. However, HXTCs possess specific, enhanced antiviral effect compared to unexpanded CD8 + T cells, consistent with results obtained in the viral inhibition assays performed without allogeneic cells (Figure 1A) , and strongly correlate with the results of the LCA (r = 0.67; P = .01; Supplementary Figure 2D ).
Responding effector cells must recognize HIV antigens induced by latency-reversing agents. We therefore confirmed our findings using a physiologically relevant exposure to the histone deacetylase (HDAC) inhibitor VOR [13] . HXTCs increased viral clearance substantially in all 3 patients tested ( Figure 1C) .
HDAC inhibition used to induce the expression of latent HIV might have deleterious immunomodulatory effects [14] . We tested the impact of physiologically relevant exposures of VOR on the antiviral capacity of CD8 + T cells. VOR concentrations peak near 335 nM at 4 hours, with rapid clearance of drug within 8 hours [13] . Pretreatment with VOR for up to 24 hours at concentrations as high as 1000 nM did not significantly impair CD8 + T-cell antiviral activity at an E:T of 1:1 or 1:10 ( Figure 2A) ; neither did VOR impair the ability of the CD8 + T cells to proliferate in response to PHA stimulation ( Figure 2B ). These results are consistent with those from a recent study, which did not find any impairment of CTL activity at physiologically relevant exposures to VOR [14] . However, it is possible that HDAC inhibitors with longer half-lives, which we did not study, may exert a negative effect on CTL function. The impact of in vivo VOR exposure on the immune response will reflect a more complex interplay of factors than can be fully modeled ex vivo. Using samples from an ongoing clinical trial (NCT01319383), we compared the antiviral capacity of CD8 + T cells obtained either before ("pre-VOR") or 6 hours following a third in vivo dose of 400 mg VOR ("post-VOR"). We found no reduction in the ability of post-VOR CD8s to inhibit productive viral infection ( Figure 2C ) or to eliminate infected cells as they emerged from latency ( Figure 2D ). In fact, at higher E:T ratios, post-VOR CD8s exerted an unexpectedly higher degree of viral inhibition than did pre-VOR CD8s (Figure 2C ), possibly reflecting antigenic stimulation resulting from transient in vivo reversal of latency, although this finding merits further evaluation.
In summary, we show that HXTCs are able to inhibit productive viral infection with autologous reservoir virus and reduce viral recovery following reactivation of resting CD4 + T cells from latency with VOR. It will be important to bear in mind that an impact on the latent reservoir may not be seen in the absence of reactivation of latency, and thus combination studies of immune therapeutics with latency-reactivating agents may be needed. Therefore, it is encouraging that we did not observe any deleterious effects of in vivo exposure of VOR on the antiviral capacity of HXTCs, providing further data to support the combination of HXTCs with VOR in future studies.
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